DRUG
Goserelin
Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation.
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin
Status
Not yet recruiting
Phase
Not applicable
Enrollment
64
Locations
5
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The non-MAC group refers to a primary conditioning regimen where the main conditioning agents-busulfan (Bu) ≤ 6.4 mg/kg, melphalan (Mel) ≤ 140 mg/m², and thiotepa ≤ 10 mg/kg-are combined. Patients receiving this primary chemotherapy regimen will be assigned to the MAC group. Within each group (MAC or non-MAC), patients were randomly assigned 1:1 to either the experimental group (goserelin prophylaxis) or the control group using a random number table. The experimental group received a single 3.6 mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation. Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; other reproductive indicators: ovarian volume, endometrial thickness; Neutrophil/platelet engraftment time; Complications: incidence of acute/chronic graft-versus-host disease (aGVHD/cGVHD), EBV/CMV infection rates; Disease recurrence rate; Transplant-related mortality; Adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in improving ovarian function following hematopoietic stem cell transplantation in patients with malignant hematologic diseases.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Apr 27, 2026
Study start
May 1, 2026
Primary completion
May 1, 2027
Study completion
Oct 1, 2027
Results posted
Not reported
Registry updated
Apr 27, 2026
Outcomes
What the study measures.
Primary outcomes
Menstrual recovery rate six months after transplantation
Time frame · month 6
Menstrual recovery rate at 6 months post-transplant, defined as the natural restoration of menstrual cycles ≥3 times without pharmacological intervention.
Secondary outcomes
Ovarian function; Safety
Time frame · month 6
(1) Incidence of premature ovarian insufficiency (POI), defined as FSH \> 25 U/L; (2) Ovarian reserve function indicators: Anti-Müllerian hormone (AMH) levels, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; (3) Other reproductive indicators: Ovarian and uterine volume, endometrial thickness; (4) Neutrophil/platelet engraftment time; (5) Incidence of acute/chronic graft-versus-host disease (aGVHD/cGVHD) and Epstein-Barr virus/cytomegalovirus (EBV/CMV) infection rates; (6) Disease recurrence rate; (7) Transplant-related mortality; (8) Adverse event (AE) occurrence.
Eligibility
Who can take part.
- Minimum age
- 14 Years
- Maximum age
- 50 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: 1\. Patients with malignant hematologic disorders scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating ability to understand and comply with all study procedures and requirements; 4. Expected survival exceeding 1 year to ensure sufficient time for monitoring menstrual recovery. Exclusion Criteria: 1\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may affect study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or other related medications; 3. Patients who have already undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may affect menstrual recovery; 6. Patients who refuse to participate in this clinical study.
Study locations
5 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The First People's Hospital of Yunnan Province
Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Goserelin.
NCT IDStudyPhase / statusEnrollmentUpdated
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI) · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8
Phase 3
Active, not recruiting
608
2026-07
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine · Breast Cancer · Cancer of Breast
Phase 2
Recruiting
50
2026-07
Effect of a GnRH Analog on Hepatic Steatosis
Aristotle University Of Thessaloniki · Metabolic Dysfunction-Associated Steatotic Liver Disease · Nonalcoholic Fatty Liver
Phase 4
Active, not recruiting
62
2026-07
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis · Early Breast Cancer
Phase 3
Recruiting
1,400
2026-07
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Eli Lilly · Breast Neoplasms
Phase 2
Recruiting
600
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.